

SCRI Trials and Trial Regimen Updates

The following updates were completed between Jan. 25, 2025, through Feb. 20, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRliKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
24130	USOR 24130 BRE 436 Phase 2 Cohort 1 (Arm 1 and 2) BNT327 + Nab-Paclitaxel Q28D USOR 24130 BRE 436 Phase 2 Cohort 2 Arm 1 BNT327 + Paclitaxel Q28D USOR 24130 BRE 436 Phase 2 Cohort 2 Arm 2 BNT327 + Gemcitabine + Carboplatin Q28D
23164	USOR 23164 LYM 240 Phase 1 Part B CB-010 USOR 23164 LYM 240 Phase 1 Part B Lymphodepletion Cyclophosphamide + Fludarabine
24086	USOR 24086 LYM 242 Phase 2 Bendamustine + Rituximab Q28D USOR 24086 LYM 242 Phase 2 Golcadomide + Rituximab Q28D USOR 24086 LYM 242 Phase 2 R-CHOP Q21D USOR 24086 LYM 242 Phase 2 Rituximab Maintenance Q56D
22260	USOR 22260 RM 949 Phase 1a/b Cohort A2, B1, B2, C1 LOXO-435 Q21D USOR 22260 RM 949 Phase 1a/b Cohort B3 LOXO-435 + Pembrolizumab Q21D

Study Number	Notes for New Build
24247	<p>USOR 24247 MM 192 Phase 3 Stage 2 Arm A (C13+) Mezigdomide + Carfilzomib D1,15 + Dexamethasone Q28D</p> <p>USOR 24247 MM 192 Phase 3 Stage 2 Arm A Mezigdomide + Carfilzomib D1,8,15 + Dexamethasone Q28D</p> <p>USOR 24247 MM 192 Phase 3 Stage 2 Arm B Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D</p> <p>USOR 24247 MM 192 Phase 3 Stage 2 Arm B Carfilzomib D1,8,15 + Dexamethasone Q28D</p>
24140	USOR 24140 AML 74 Phase 1a/1b NMS-03597812 Q28D

Updated Reference Information

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
22322	Amendment f: 22 Aug 2024	NA	NA
23245	Amendment 01 Version 2.0: 11 Oct 2024	NA	NA
20186	Version 6: 25 October 2024	NA	NA
23141	Protocol Amendment 07: 13 Dec 2024	NA	NA
23076	Version 4: 31OCT2024	Order of administration updated	NA
22325	NA	Update IP preparation	NA
23229	NA	Update IP preparation	NA

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
22067	NA	Update IP preparation	NA
23223	Version 6.0: 19 Sep 2024	Update IP administration language	Updated regimen title to include drug name
23059	Version 3: 06 Sep 2024	NA	NA
23141	Protocol Amendment 07: 13 Dec 2024	NA	NA
21455	Version 5: 02 Oct 2024	NA	NA
23051	NA	Update IP preparation	NA
18283	Amendment 13: 19 Nov, 2024	Update IP preparation	NA